Inhalon
William P. is a seasoned financial advisor specializing in life science companies, currently self-employed in that capacity. Previously, William served as Chief Financial Officer at both Harpoon Therapeutics and Pearl Therapeutics, where expertise in financial leadership was demonstrated. Prior experience includes the role of Director of Financial and Business Planning at Nektar Therapeutics, as well as consulting for marketing and new product planning at Objective Insights, Inc. William holds a Bachelor of Arts degree from the University of Notre Dame and a degree from San Jose State University.
This person is not in any teams
This person is not in any offices
Inhalon
Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.